Merck: A Dividend’s Shadow

by

Merck, they say, has climbed 46% in a year. A curious spectacle. One might expect a company facing the predictable decline of its HPV vaccines – Gardasil, Gardasil 9, the names themselves echoing a faintly desperate optimism – to be, shall we say, less buoyant. And then there’s Keytruda, the cancer drug, the golden goose, the object of so much hopeful accounting. A goose, alas, with a rapidly approaching expiration date. The market, it seems, is in the grip of a collective delusion, or perhaps a particularly well-funded publicist.

Still, one should not dismiss the possibility of profit. Not entirely. It’s a grim business, this chasing of dividends, like scavenging for crumbs beneath the table of pharmaceutical giants. But crumbs, when accumulated, can sustain a man. Or at least, a portfolio.

The Fading Halo of Keytruda

Keytruda, the world’s most celebrated oncology product, is, of course, destined for obsolescence. The patent cliff looms, a precipice over which all pharmaceutical empires eventually tumble. And the vultures are gathering. Summit Therapeutics, with its ivonescimab, has dared to challenge the reigning champion. A head-to-head trial, they claim, in the labyrinthine world of non-small cell lung cancer. One can almost hear the frantic recalculations of the analysts, the hurried revisions of their optimistic projections.

Merck, to its credit, has attempted a palliative measure: a subcutaneous formulation. Faster, easier administration. A cosmetic improvement, perhaps, but one that might delay the inevitable. It’s akin to applying rouge to a corpse – a temporary illusion of vitality. There will be ‘Keytruda killers,’ undoubtedly. The pharmaceutical world is littered with the ghosts of vanquished blockbusters. But Merck, with its vast network of indications and its carefully cultivated reputation, may yet cling to a respectable share of the market. A slow decline, rather than a catastrophic collapse. It’s a difference, though a subtle one.

Loading widget...

Beyond the Golden Goose

Merck, it appears, has been diversifying. Winrevair, for pulmonary arterial hypertension, and Capvaxive, a pneumonia vaccine. Solid sales, they claim. Over a billion dollars for Winrevair. A rounding error, perhaps, in the grand scheme of things, but a welcome one nonetheless. And a pipeline brimming with ‘promising candidates,’ including a potential revolution in influenza vaccination. The usual promises. Merck has been playing this game for decades: developing new products to replace the old, maintaining a semblance of stability amidst the chaos of scientific progress and market forces. It’s a tedious, unglamorous process, but remarkably effective.

The dividend, of course, is the lure. 93.8% increase over a decade. A payout ratio of 45.1%. Ample room for further hikes, they assure us. A forward yield of 2.8%, comfortably above the S&P 500 average of 1.2%. A modest return, perhaps, but a predictable one. Like the ticking of a clock, it offers a small measure of comfort in a world spiraling towards entropy.

So, even with the Keytruda patent cliff looming, even with the challenges facing its HPV vaccine business, Merck remains… tolerable. Not a great investment, certainly. Not a visionary opportunity. But a reasonably safe harbor for capital, in a sea of uncertainty. A place to wait, perhaps, for something… less predictable. Or, failing that, for the inevitable collapse of the entire system. One must be prepared for all eventualities, after all.

Read More

2026-02-22 23:53